{"DataElement":{"publicId":"6438456","version":"1","preferredName":"Chronic Myeloid Leukemia Pathway Patient Prior Enrollment Tyrosine Kinase Inhibitor Therapeutic Procedure Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The response that indicates the patient meets the eligibility requirements for participation in a clinical trial with regards to patient's prior therapy with TKI prior to enrollment.","longName":"PT_TKI_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"6438444","version":"1","preferredName":"Chronic Myeloid Leukemia Pathway Patient Prior Enrollment Tyrosine Kinase Inhibitor Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, haematopoietic stem cells (HSCs). HSCs can differentiate into common myeloid progenitors (CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs). HSCs can also differentiate into common lymphoid progenitors (CLPs), which are the progenitors of lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) is characterized by a massive expansion of the granulocytic-cell series. Acquisition of additional genetic mutations beyond expression of BCR/ABL causes the progression of CML from chronic phase to blast phase (CML-BP), characterized by an accumulation of myeloid or lymphoid blast cells._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Earlier in time or order._The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled._Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6438422v1.0:6438442v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6438422","version":"1","preferredName":"Chronic Myeloid Leukemia Pathway Patient","preferredDefinition":"Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, haematopoietic stem cells (HSCs). HSCs can differentiate into common myeloid progenitors (CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs). HSCs can also differentiate into common lymphoid progenitors (CLPs), which are the progenitors of lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) is characterized by a massive expansion of the granulocytic-cell series. Acquisition of additional genetic mutations beyond expression of BCR/ABL causes the progression of CML from chronic phase to blast phase (CML-BP), characterized by an accumulation of myeloid or lymphoid blast cells.:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"C91465:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia Pathway","conceptCode":"C91465","definition":"Chronic myelogenous leukaemia (CML) is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, haematopoietic stem cells (HSCs). HSCs can differentiate into common myeloid progenitors (CMPs), which then differentiate into granulocyte/macrophage progenitors (GMPs). HSCs can also differentiate into common lymphoid progenitors (CLPs), which are the progenitors of lymphocytes such as T cells and B cells. The initial chronic phase of CML (CML-CP) is characterized by a massive expansion of the granulocytic-cell series. Acquisition of additional genetic mutations beyond expression of BCR/ABL causes the progression of CML from chronic phase to blast phase (CML-BP), characterized by an accumulation of myeloid or lymphoid blast cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76C8A94C-31EB-2F60-E053-F662850AB96F","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-26","modifiedBy":"ONEDATA","dateModified":"2018-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6438442","version":"1","preferredName":"Prior Enrollment Tyrosine Kinase Inhibitor Therapeutic Procedure Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order.:The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled.:Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6438442v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Enrollment","conceptCode":"C37948","definition":"The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tyrosine Kinase Inhibitor","conceptCode":"C1967","definition":"Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76C72E8B-3D60-6330-E053-F662850A424C","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-26","modifiedBy":"ONEDATA","dateModified":"2018-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76C72E8B-3D71-6330-E053-F662850A424C","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-26","modifiedBy":"LEEW","dateModified":"2018-11-05","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506035","version":"1","preferredName":"Yes No Unknown Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/unknown/not applicable.","longName":"YES_NO_UNKNOWN_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D41-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D4B-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D55-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D5F-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694968","version":"1","preferredName":"Ind-4","preferredDefinition":"A response or indicator that can have a value of yes, no, unknown, or not applicable.","longName":"C49486","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, Unknown, or Not Applicable Response","conceptCode":"C49486","definition":"A response or indicator that can have a value of yes, no, unknown, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCAFD6-ECF0-4640-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 requested By Tina Taylor approved by Dianne Reeves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C379D9D0-6D2D-CCDD-E040-BB89AD432590","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"COOPERM","dateModified":"2020-08-13","changeDescription":"3/12/17 jk added Standard reg status; ownership  transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 3/23/16 jk value \"Not evaluable\" added in error by COG on 3/21/16 was removed.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Has patient been receiving th","type":"Preferred Question Text","description":"Has patient been receiving their current TKI for a minimum of 3 consecutive years at the time of enrollment?","url":null,"context":"COG"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Has patient received any TKI for a minimum of 3 consecutive years at the time of enrollment?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76CA0788-8E9D-4B53-E053-F662850A0FA5","latestVersionIndicator":"Yes","beginDate":"2018-09-26","endDate":null,"createdBy":"LEEW","dateCreated":"2018-09-26","modifiedBy":"LEEW","dateModified":"2021-02-03","changeDescription":"AAML18P1","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}